Key Takeaways
- • Breyer Capital appointed Dr. Bret Bostwick, a physician-scientist and drug developer, as Venture Advisor to strengthen its healthcare and life sciences practice, according to a Business Wire announcement.
- • Bostwick previously served as Senior Medical Director at Alnylam Pharmaceuticals, where he co-invented multiple CNS-targeted RNAi therapeutics and led translational work on mivelsiran, described as the first siRNA to demonstrate gene silencing in the human brain.
- • Bostwick will work with Dr. Morgan Cheatham, Partner and Head of Healthcare & Life Sciences, and Founder and CEO Jim Breyer to build an integrated investment platform spanning drug discovery through care delivery.
- • The appointment places Bostwick alongside Sam Palmisano, former IBM CEO and Chairman, in Breyer's Venture Advisor group.
Summary
Breyer Capital, a venture capital firm founded by Jim Breyer in 2006, has named Dr. Bret Bostwick as Venture Advisor, according to a Business Wire release dated December 19, 2025. The firm said the appointment is intended to deepen its therapeutics and life sciences strategy. Dr. Bostwick will work closely with Dr. Morgan Cheatham, Partner and Head of Healthcare & Life Sciences, who leads the firm's sector investment strategy, and with Jim Breyer. Together, the team aims to build an integrated healthcare and life sciences platform spanning drug discovery through care delivery.
In the advisory role, Bostwick will support investment, incubation, and portfolio efforts across therapeutics and life sciences, contributing translational and clinical judgment. The firm said his perspective will add rigor to how it evaluates early science and supports companies as programs progress from discovery into development.
Bostwick's background includes senior leadership across translational medicine, drug discovery, and clinical development. Before joining Breyer, he served as Senior Medical Director at Alnylam Pharmaceuticals, where he co-invented multiple CNS-targeted RNAi therapeutics and led translational work supporting mivelsiran. He previously was Chief of Pediatric Genetics at Texas Children's Hospital and held a faculty appointment at Baylor College of Medicine as a clinical medical geneticist. He currently leads Translational Medicine Solutions, an advisory firm focused on healthcare, technology, and venture capital.
Cheatham described the hire as an "exciting inflection point" for the healthcare and life sciences practice. Breyer said Bostwick's experience across academic medicine, biotechnology, and venture investing gives him a rare perspective on how scientific ideas become actionable programs. Bostwick joins Sam Palmisano, former CEO and Chairman of IBM, among others in the Venture Advisor group. Breyer's portfolio includes companies such as OpenEvidence, Facebook, Meta, Spotify, and Circle, according to the firm's description.
In the advisory role, Bostwick will support investment, incubation, and portfolio efforts across therapeutics and life sciences, contributing translational and clinical judgment. The firm said his perspective will add rigor to how it evaluates early science and supports companies as programs progress from discovery into development.
Bostwick's background includes senior leadership across translational medicine, drug discovery, and clinical development. Before joining Breyer, he served as Senior Medical Director at Alnylam Pharmaceuticals, where he co-invented multiple CNS-targeted RNAi therapeutics and led translational work supporting mivelsiran. He previously was Chief of Pediatric Genetics at Texas Children's Hospital and held a faculty appointment at Baylor College of Medicine as a clinical medical geneticist. He currently leads Translational Medicine Solutions, an advisory firm focused on healthcare, technology, and venture capital.
Cheatham described the hire as an "exciting inflection point" for the healthcare and life sciences practice. Breyer said Bostwick's experience across academic medicine, biotechnology, and venture investing gives him a rare perspective on how scientific ideas become actionable programs. Bostwick joins Sam Palmisano, former CEO and Chairman of IBM, among others in the Venture Advisor group. Breyer's portfolio includes companies such as OpenEvidence, Facebook, Meta, Spotify, and Circle, according to the firm's description.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.